Clinically useful predictors of treatment outcome in major depressive disorder (MDD) remain elusive. We examined associations between functional magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) signal during active negative word processing and subsequent selective serotonin reuptake inhibitor (SSRI) treatment outcome in MDD. Unmedicated MDD subjects (n ¼17) performed an emotional word processing fMRI task, and then received eight weeks of standardized antidepressant treatment with escitalopram. Lower pre-treatment BOLD responses to negative words in midbrain, dorsolateral prefrontal cortex, paracingulate, anterior cingulate, thalamus and caudate nuclei correlated significantly with greater improvement following escitalopram treatment. Activation of these regions in response to negative words correlated significantly with reaction time for rating word relevance. Maximally predictive clusters of voxels identified using a cross-validation approach predicted 48% of the variance in response to treatment. This study provides preliminary evidence that SSRIs may be most beneficial in patients who are less able to engage cognitive control networks while processing negative stimuli. Differences between these findings and previous fMRI studies of SSRI treatment outcome may relate to differences in task design. Regional BOLD responses to negative words predictive of SSRI outcome in this study were both overlapping and distinct from those predictive of outcome with cognitive behavioral therapy (CBT) in previous studies using the same task. Future studies may examine prediction of differential outcome across treatments in the context of a randomized controlled trial.
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Introduction
Biomarkers to predict treatment outcome with pharmacotherapy for major depressive disorder (MDD) are needed. Correlates of neural activity in the anterior cingulate cortex (ACC) and its subregions have been implicated in treatment outcome in MDD with some consistency (Pizzagalli, 2011), although no brain imaging measures are used to date in routine clinical practice. Functional MRI (fMRI) studies have found neural response to negative emotional stimuli in anterior cingulate cortex (ACC) (Davidson et al., 2003; Chen et al., 2007) , subgenual ACC (sgACC) (Fu et al., 2004; Keedwell et al., 2010) , and pregenual/rostral ACC (rACC) (Langenecker et al., 2007; Ruhe et al., 2012) to be associated with better response to antidepressant medication treatment (with selective serotonin reuptake inhibitors (SSRIs), serotonin/ norepinephrine reuptake inhibitors (SNRIs), or open treatment). In partial contrast, one of these studies found higher sgACC responses to be associated with worse treatment response (Ruhe et al., 2012) . Along the same lines, several (Mayberg et al., 1997 (Mayberg et al., , 2000 but not all (Konarski et al., 2z009) studies of resting glucose metabolism have found that higher pre-treatment activity in sgACC and rACC as well as rACC electroencephalography (EEG) (Pizzagalli et al., 2001 ) predict better treatment response. While these largely convergent studies implicate ACC in treatment response to antidepressant medications, responses in other brain regions, including amygdala, have also been associated with SSRI outcome in MDD (Victor et al., 2010 
